Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Capillary Hemangioma
100%
Hemangioma
70%
Pediatrics
36%
Rapamycin
34%
COVID-19
34%
Propranolol
29%
Pediatrics Patient
29%
Hamartoma
27%
Venous Ulcer
26%
Rapidly Involuting Congenital Hemangioma
23%
Congenital Malformation
23%
Rituximab
20%
Vascular Tissue Neoplasm
20%
Vascular Anomaly
20%
Eczema
19%
Dermatology
19%
Atopic Dermatitis
18%
Capillary
18%
Pediatric Dermatology
18%
Neonates
18%
Lupus Erythematosus Panniculitis
18%
Neurofibromatosis Type I
17%
Subacute Cutaneous Lupus Erythematosus
17%
Arteriovenous Malformation
17%
Juvenile Dermatomyositis
17%
Myositis
17%
Trametinib
17%
Skin Manifestation
17%
Involution
17%
Infancy
16%
Infection
15%
Dermatological Agent
15%
Tumor
14%
Oral
14%
Papule
14%
Adolescence
13%
Nevus
13%
Diseases
12%
Alopecia Areata
12%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Dermatitis
11%
Pediatrician
11%
Clinical Decision Making
11%
Vasculitis
11%
Psoriasis
10%
Malformation Syndrome
10%
Dermatomyositis
10%
Polymyositis
10%
Hemangioendothelioma
10%
Folliculitis
9%
Keyphrases
Infantile Hemangioma
77%
Topical Sirolimus
25%
Natural History
23%
Hemangioma
21%
Vascular Anomalies
21%
Rituximab
20%
Congenital Hemangioma
19%
COVID-19
19%
Atopic Dermatitis
19%
Rapidly Involuting Congenital Hemangioma
17%
Propranolol
17%
Reactive Infectious mucocutaneous Eruption
17%
Neurofibromatosis Type 1 (NF-1)
17%
Cutaneous Lupus Erythematosus
17%
Oral Propranolol
15%
Pediatric Patients
15%
Clinical Features
14%
Dermatological Diseases
13%
Macules
13%
Blister
12%
Pediatric Dermatology
12%
Quality of Life
12%
Vascular Tumor
12%
Systemic Therapy
11%
Subcutis
11%
Caregivers
11%
Disfigurement
11%
Bleeding
10%
Involute
10%
Noninvoluting Congenital Hemangioma
10%
Current Management
10%
Papules
10%
Pediatric
10%
Cutaneous Findings
10%
BRAF Fusion
10%
Neonate
9%
Extracutaneous
9%
Neurovascular
9%
Mucocutaneous Eruptions
9%
Vasculitis
9%
Panniculitis
9%
Pediatric Rheumatology
9%
Successful Treatment
9%
Cutaneous Reaction
8%
Trametinib
8%
Arteriovenous Malformation
8%
European League against Rheumatism (EULAR)
8%
Juvenile Dermatomyositis
8%
Retrospective Review
8%
Dupilumab
8%